Oliver J. Stoetzer

853 total citations
29 papers, 625 citations indexed

About

Oliver J. Stoetzer is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Oliver J. Stoetzer has authored 29 papers receiving a total of 625 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Cancer Research. Recurrent topics in Oliver J. Stoetzer's work include Cancer Treatment and Pharmacology (6 papers), Advanced Breast Cancer Therapies (4 papers) and Breast Cancer Treatment Studies (4 papers). Oliver J. Stoetzer is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Advanced Breast Cancer Therapies (4 papers) and Breast Cancer Treatment Studies (4 papers). Oliver J. Stoetzer collaborates with scholars based in Germany, United States and France. Oliver J. Stoetzer's co-authors include Stefan Holdenrieder, Barbara Siegele, Debora M.I. Fersching, Christoph Salat, Volker Heinemann, R. Pelka‐Fleischer, W. Wilmanns, Gloria Leszinski, Dorothea Nagel and V. Nüßler and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Oliver J. Stoetzer

28 papers receiving 608 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Oliver J. Stoetzer Germany	14	256	206	113	98	97	29	625
Shunji Miki Japan	9	189 0.7×	231 1.1×	82 0.7×	17 0.2×	91 0.9×	15	651
Saskia A.G.M. Cillessen Netherlands	18	275 1.1×	279 1.4×	88 0.8×	89 0.9×	62 0.6×	37	832
Lizhen Gui United States	8	330 1.3×	94 0.5×	112 1.0×	76 0.8×	69 0.7×	9	580
Denise L. Cecil United States	14	278 1.1×	200 1.0×	78 0.7×	19 0.2×	54 0.6×	29	621
Qinchuan Li China	18	470 1.8×	186 0.9×	340 3.0×	29 0.3×	187 1.9×	49	922
Kan Wu China	15	341 1.3×	221 1.1×	229 2.0×	47 0.5×	211 2.2×	77	776
Xiaoyan Qiu China	11	399 1.6×	126 0.6×	85 0.8×	17 0.2×	63 0.6×	26	618
Daniel H. Wiseman United Kingdom	15	529 2.1×	96 0.5×	78 0.7×	104 1.1×	37 0.4×	46	854
Canan Cacına Türkiye	16	300 1.2×	182 0.9×	89 0.8×	30 0.3×	41 0.4×	39	567

Countries citing papers authored by Oliver J. Stoetzer

Since Specialization

Citations

This map shows the geographic impact of Oliver J. Stoetzer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver J. Stoetzer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver J. Stoetzer more than expected).

Fields of papers citing papers by Oliver J. Stoetzer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver J. Stoetzer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver J. Stoetzer. The network helps show where Oliver J. Stoetzer may publish in the future.

Co-authorship network of co-authors of Oliver J. Stoetzer

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver J. Stoetzer. A scholar is included among the top collaborators of Oliver J. Stoetzer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver J. Stoetzer. Oliver J. Stoetzer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gezer, Uğur, et al.. (2024). Targeted Sequencing of Human Satellite 2 Repeat Sequences in Plasma cfDNA Reveals Potential Breast Cancer Biomarkers. Diagnostics. 14(6). 609–609. 2 indexed citations

Braun, Michael, Monika Kriner, Claus Hanusch, et al.. (2021). Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level. Breast Care. 17(3). 288–295. 2 indexed citations

Pölcher, Martin, Michael Braun, Moritz Hamann, et al.. (2021). Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer. Archives of Gynecology and Obstetrics. 304(3). 783–790. 10 indexed citations

Wuerstlein, Rachel, Nadia Harbeck, Eva‐Maria Grischke, et al.. (2020). Protroca: A Noninterventional Study on Prophylactic Lipegfilgrastim against Chemotherapy-Induced Neutropenia in Nonselected Breast Cancer Patients. Breast Care. 16(1). 50–58.

Stoetzer, Oliver J., Dorit Di Gioia, Rolf D. Issels, et al.. (2020). Post-Neoadjuvant Gemcitabine and Cisplatin with Regional Hyperthermia for Patients with Triple-Negative Breast Cancer and Non-pCR after Neoadjuvant Chemotherapy: A Single-Institute Experience. Breast Care. 16(2). 173–180. 4 indexed citations

Schmohl, Joerg Uwe, Thomas Guenther, Friedhelm R. Schuster, et al.. (2020). Expression profiles of HMGB1 on B-CLL related leukocytes contribute to prediction of relapse. Immunobiology. 226(1). 152048–152048. 2 indexed citations

Einem, Jobst C. von, Christine Guenther, Hans‐Dieter Volk, et al.. (2019). Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial. International Journal of Cancer. 145(6). 1538–1546. 56 indexed citations

Tesch, Hans, Oliver J. Stoetzer, Thomas Decker, et al.. (2018). Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial. International Journal of Cancer. 144(4). 877–885. 31 indexed citations

Hadji, Peyman, Oliver J. Stoetzer, Thomas Decker, et al.. (2018). The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. Journal of bone oncology. 14. 100199–100199. 4 indexed citations

10.

Wilhelm, Martin, Lothar Mueller, Michael Craig Miller, et al.. (2016). Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. Clinical Colorectal Cancer. 15(4). 381–388. 54 indexed citations

11.

Tesch, Hans, Oliver J. Stoetzer, Thomas Decker, et al.. (2015). Abstract P5-19-06: 4EVER - Final efficacy analysis of the phase IIIb, multi-center, open label study for postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer (BC) treated with everolimus (EVE) in combination with exemestane (EXE). Cancer Research. 75(9_Supplement). P5–19. 3 indexed citations

12.

Kunzmann, Volker, Michael Craig Miller, Stefan Holdenrieder, et al.. (2015). A prospective, multi-center study of individualized, pharmacokinetically (PK)-guided dosing of 5-fluorouracil (5-FU) in metastatic colorectal cancer (mCRC) patients treated with weekly or biweekly 5-FU/oxaliplatin containing regimens.. Journal of Clinical Oncology. 33(15_suppl). 3542–3542. 3 indexed citations

13.

Stoetzer, Oliver J., Debora M.I. Fersching, Christoph Salat, et al.. (2013). Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin. Cancer Letters. 336(1). 140–148. 37 indexed citations

14.

Leszinski, Gloria, Uğur Gezer, Barbara Siegele, Oliver J. Stoetzer, & Stefan Holdenrieder. (2012). Relevance of histone marks H3K9me3 and H4K20me3 in cancer.. PubMed. 32(5). 2199–205. 52 indexed citations

15.

Stoetzer, Oliver J., Debora M.I. Fersching, Christoph Salat, et al.. (2012). Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy. Tumor Biology. 34(1). 81–90. 68 indexed citations

16.

Stoetzer, Oliver J., et al.. (2012). Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy. Expert Opinion on Biological Therapy. 12(sup1). S217–S224. 18 indexed citations

17.

Schleuning, Michael, et al.. (2002). Hematopoietic stem cell transplantation after reduced-intensity conditioning as treatment of sickle cell disease. Experimental Hematology. 30(1). 7–10. 35 indexed citations

18.

Stoetzer, Oliver J., et al.. (2002). Modulation of apoptosis by mitochondrial uncouplers: apoptosis-delaying features despite intrinsic cytotoxicity. Biochemical Pharmacology. 63(3). 471–483. 21 indexed citations

19.

Kolb, H., Christoph Schmid, Maja Weisser, et al.. (2002). Cytoreduction, DLI, or mobilized peripheral blood progenitors.. PubMed. 81 Suppl 2. S30–3. 3 indexed citations

20.

Stoetzer, Oliver J., et al.. (1997). Reduced expression of the ICE-related protease CPP32 is associated with radiation-induced cisplatin resistance in HeLa cells. British Journal of Cancer. 76(10). 1322–1327. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact